# IMFINZI® (durvalumab) HCP - **Website:** - **Primary alias:** `imfinzihcp.com` - **Employees:** 2+ - **Company kind:** PUBLIC COMPANY ## Description IMFINZI® (durvalumab) is an immunotherapy brand that offers innovative treatment options for adult patients with various types of cancer. It is specifically designed for patients with metastatic NSCLC, unresectable Stage III NSCLC, extensive-stage SCLC, advanced or metastatic BTC, and unresectable HCC. As an immunotherapy, IMFINZI® (durvalumab) works by activating the immune system to fight against cancer cells. It can be used as a standalone treatment or in combination with other medications, such as IMJUDO. For patients with unresectable Stage III non-small cell lung cancer, IMFINZI® (durvalumab) is prescribed after concurrent platinum-based chemotherapy and radiation therapy. It has shown efficacy in improving overall survival and progression-free survival rates. In addition, IMFINZI® (durvalumab) has demonstrated promising results in treating patients with metastatic NSCLC, extensive-stage SCLC, advanced or metastatic BTC, and unresectable HCC. It has been shown to effectively prolong survival rates and improve treatment outcomes. Doctors and healthcare professionals can find valuable prescribing information, clinical guidelines, safety information, dosing recommendations, and medical resources on the brand's website. IMFINZI® (durvalumab) is dedicated to providing support and resources to both healthcare professionals and patients on their cancer treatment journeys. ## Industries - 🏭 Chemical Industry _(under Heavy Industry and Engineering)_ - 🏭 Heavy Industry and Engineering ## Logos & icons - logo _(primary)_ — PNG — [download](https://cdn.brandfetch.io/ideHwpaKKj/w/250/h/67/theme/light/logo.png?c=1bxid64Mup7aczewSAYMX&t=1772055208896) ## Colors | Name | Hex | Theme | | --- | --- | --- | | Di Serria | #d6964a | accent | | Black | #000000 | dark | | Jordy Blue | #6bbaef | light | ## Fonts - SolexOT-Regular — asset _(custom)_ - Roboto-Light — asset _(custom)_ --- _Source: _ _See [/llms.txt](/llms.txt) for a full list of agent-readable pages, and [/auth.md](/auth.md) for how agents authenticate._